{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:44:03Z","timestamp":1794278643878,"version":"4.9.0"},"reference-count":52,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,7,25]]},"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Immunosuppressed individuals are at a high risk of latent tuberculosis infection (LTBI) and clinical practice guidelines for the screening and management of LTBI in at-risk patients have been developed. We assessed the scope, quality and consistency of clinical practice guidelines on screening for LTBI and the prevention of tuberculosis infection (TB) in high-risk patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We conducted a systematic review of clinical practice guidelines. Methodological quality of these guidelines was assessed using the Appraisal of Guidelines for Research and Education (AGREE) II instrument. Textual synthesis was used to summarise and compare the recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Electronic databases (MEDLINE, EMBASE, PsycINFO) and guideline registries were searched from inception to December 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-eight guidelines were included. Nineteen focused on patients receiving medical immunosuppression, seven on transplantation, three on patients with HIV and nine were generalised across all at risk populations. Most guidelines (n=32, 84%) used a systematic approach to identify and appraise the evidence. The methodological quality of the guidelines varied with the overall mean AGREE II scores ranging from 35% to 80%. Guidelines performed poorly in terms of editorial independence (average score 35%, range 0%\u201392%); however, most were robust in defining their scope and purpose (average score 80%, range 56%\u2013100%). Guidelines recommended either or both the tuberculin skin test and the interferon gamma release assay for screening. Treatment of LTBI with isoniazid was consistently recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical practice guidelines on LTBI vary in quality and scope. The recommendations for screening varied across guidelines, while recommendations for treatment were largely consistent. Improving the consistency and quality of guidelines may help to optimise the screening and management of LTBI for improved patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-022445","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T10:45:25Z","timestamp":1536749125000},"page":"e022445","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":76,"title":["Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines"],"prefix":"10.1136","volume":"8","author":[{"given":"Tasnim","family":"Hasan","sequence":"first","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Au","sequence":"additional","affiliation":[{"name":"Centre for Transplant and Renal Research, Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales, Australia"},{"name":"School of Medicine, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Tong","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children\u2019s Hospital, Westmead, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine","family":"Wong","sequence":"additional","affiliation":[{"name":"Centre for Transplant and Renal Research, Westmead Hospital, Westmead, New South Wales, Australia"},{"name":"Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,9,12]]},"reference":[{"key":"2025121510493308000_8.9.e022445.1","unstructured":"Australian Rheumatology Association. Screening for latent tuberculosis infection (LTBI) prior to use of biological agents in Australia. 2010. https:\/\/rheumatology.org.au\/downloads\/April2010-FINAL-SCREENINGFORLATENTTUBERCULOSISINFECTION.pdf (accessed 25 Oct 2016)."},{"key":"2025121510493308000_8.9.e022445.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"2025121510493308000_8.9.e022445.3","doi-asserted-by":"publisher","DOI":"10.1086\/597590"},{"key":"2025121510493308000_8.9.e022445.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70013-9"},{"key":"2025121510493308000_8.9.e022445.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"2025121510493308000_8.9.e022445.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"2025121510493308000_8.9.e022445.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"2025121510493308000_8.9.e022445.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20009"},{"key":"2025121510493308000_8.9.e022445.9","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2016 https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf (accessed 27 Oct 2016)."},{"key":"2025121510493308000_8.9.e022445.10","unstructured":"World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015."},{"key":"2025121510493308000_8.9.e022445.11","first-page":"55","article-title":"Challenges of interferon- \u03b3 release assay conversions in serial testing of health-care workers in a TB control program","volume":"142","author":"Kong","year":"2011","journal-title":"Chest"},{"key":"2025121510493308000_8.9.e022445.12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00730-12"},{"key":"2025121510493308000_8.9.e022445.13","doi-asserted-by":"crossref","unstructured":"Field MJ , Lohr KN . Committee to Advise the Public Health Service on Clinical Practice Guidelines, Institute of Medicine. Clinical practice guidelines: directions of a new program. Washington, DC: National Academy Press, 1990.","DOI":"10.17226\/1626"},{"key":"2025121510493308000_8.9.e022445.14","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090449"},{"key":"2025121510493308000_8.9.e022445.15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4414\/smw.2007.11939","article-title":"Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy","volume":"137","author":"Beglinger","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"2025121510493308000_8.9.e022445.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.011"},{"key":"2025121510493308000_8.9.e022445.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.023"},{"key":"2025121510493308000_8.9.e022445.18","first-page":"290","article-title":"Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy","volume":"37","author":"Duarte","year":"2012","journal-title":"Acta Reumatol Port"},{"key":"2025121510493308000_8.9.e022445.19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0873-2159(15)30235-X","article-title":"Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors - March 2008 update","volume":"14","author":"Fonseca","year":"2008","journal-title":"Rev Port Pneumol"},{"key":"2025121510493308000_8.9.e022445.20","doi-asserted-by":"publisher","DOI":"10.7196\/samj.7047"},{"key":"2025121510493308000_8.9.e022445.21","first-page":"6","article-title":"Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee","volume":"101","author":"Kavanagh","year":"2008","journal-title":"Ir Med J"},{"key":"2025121510493308000_8.9.e022445.22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13355"},{"key":"2025121510493308000_8.9.e022445.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-007-0626-3"},{"key":"2025121510493308000_8.9.e022445.24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1479-8077.2006.00182.x","article-title":"Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents","volume":"9","author":"Lichauco","year":"2006","journal-title":"APLAR Journal of Rheumatology"},{"key":"2025121510493308000_8.9.e022445.25","first-page":"170","article-title":"Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint, Bone","volume":"69","author":"Salmon","year":"2002","journal-title":"Spine"},{"key":"2025121510493308000_8.9.e022445.26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Consensus document on prevention and treatment of tuberculosis in patients for biological treatment","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"2025121510493308000_8.9.e022445.27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1596-y"},{"key":"2025121510493308000_8.9.e022445.28","first-page":"C4480","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen","year":"2012","journal-title":"Dan Med J"},{"key":"2025121510493308000_8.9.e022445.29","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046797"},{"key":"2025121510493308000_8.9.e022445.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09505.x"},{"key":"2025121510493308000_8.9.e022445.31","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"2025121510493308000_8.9.e022445.32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"2025121510493308000_8.9.e022445.33","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000712"},{"key":"2025121510493308000_8.9.e022445.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"issue":"Suppl 7","key":"2025121510493308000_8.9.e022445.35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1469-0691.12641","article-title":"Mycobacterial infections in solid organ transplant recipients","volume":"20","author":"Meije","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2025121510493308000_8.9.e022445.36","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.1.50"},{"issue":"Suppl 4","key":"2025121510493308000_8.9.e022445.37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/ajt.12100","article-title":"Mycobacterium tuberculosis infections in solid organ transplantation","volume":"13","author":"Subramanian","year":"2013","journal-title":"Am J Transplant"},{"key":"2025121510493308000_8.9.e022445.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"2025121510493308000_8.9.e022445.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2011.00954.x"},{"key":"2025121510493308000_8.9.e022445.40","unstructured":"Republic of South Africa Department of Health. Guidelines for tuberculosis preventive therapy among HIV infected individuals in South Africa. 2010 www.who.int\/hiv\/pub\/guidelines\/south_africa_hiv_tb.pdf (accessed 1 Nov 2016)."},{"key":"2025121510493308000_8.9.e022445.41","doi-asserted-by":"crossref","first-page":"303.e1","DOI":"10.1016\/j.eimc.2015.11.022","article-title":"Guidelines for the use of interferon-\u03b3 release assays in the diagnosis of tuberculosis infection","volume":"34","author":"Santin","year":"2016","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"2025121510493308000_8.9.e022445.42","doi-asserted-by":"publisher","DOI":"10.4103\/0256-4947.59373"},{"key":"2025121510493308000_8.9.e022445.43","unstructured":"European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: European Centre for Disease Prevention and Control (ECDC), 2011."},{"issue":"RR-5","key":"2025121510493308000_8.9.e022445.44","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"RR-12","key":"2025121510493308000_8.9.e022445.45","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"Acs-6","key":"2025121510493308000_8.9.e022445.46","first-page":"1","article-title":"Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS)","volume":"34","author":"Canadian Tuberculosis Committee","year":"2008","journal-title":"Can Commun Dis Rep"},{"key":"2025121510493308000_8.9.e022445.47","first-page":"21","article-title":"Treatment guidelines for latent tuberculosis infection","volume":"89","author":"Prevention Committee of the Japanese Society for Tuberculosis","year":"2014","journal-title":"Kekkaku"},{"key":"2025121510493308000_8.9.e022445.48","unstructured":"National Collaborating Centre for Chronic Conditions (UK): Centre for Clinical Practice at NICE (UK). Tuberculosis: prevention, diagnosis, management and service organisation. London: National Institure for Health and Clinical Excellence (UK), 2016."},{"key":"2025121510493308000_8.9.e022445.49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.4.436"},{"key":"2025121510493308000_8.9.e022445.50","first-page":"293","article-title":"Mycobacterium tuberculosis infection in health care workers in rural India: Comparison of a whole blood interferon-\u03b3 assay with tuberculin skin testing","volume":"22","author":"Pai","year":"2005","journal-title":"JAMA"},{"key":"2025121510493308000_8.9.e022445.51","first-page":"895","article-title":"Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models","volume":"12","author":"Pai","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121510493308000_8.9.e022445.52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188631","article-title":"Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis","volume":"12","author":"Doan","year":"2017","journal-title":"PLoS One"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-022445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:49:39Z","timestamp":1765824579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-022445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,12]]},"published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1136\/bmjopen-2018-022445"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-022445","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2018-022445.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}